Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

100.50 -1.55 (-1.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Jazz Pharmaceuticals Completes U.S. Divestiture Of Sunosi To Axsome Therapeutics, What's Next?
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has completed the divestiture of Sunosi (solriamfetol) in the U.S. 
Via Benzinga
What 6 Analyst Ratings Have To Say About Jazz Pharmaceuticals
Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Jazz Pharma, Sumitomo Pharma Ink Licensing Pact For Sleeping Disorder Candidate
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Werewolf Therapeutics Shares Jump On Cancer Product Pact With Jazz Pharma
Via Benzinga
Earnings Scheduled For March 1, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga
Jazz Pharma Reports Q1 Epidiolex Sales Increased 6% To $157.9M YoY
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) released financial results for the first quarter of 2022. 
Via Benzinga
Jazz Pharmaceuticals: Q1 Earnings Insights
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported its Q1 earnings results on Wednesday, May 4, 2022 at 05:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
EXCLUSIVE: Aurora Cannabis CEO 'Absolutely Confident' Company Will Be EBITDA-Positive By Year's End
Miguel Martin, CEO of Aurora Cannabis Inc (NASDAQ: ACB), discussed growing Aurora into the leader of the international medical cannabis market at the Benzinga Cannabis Capital Conference on Wednesday. 
Via Benzinga
Axsome Therapeutics Stock Rockets As Its First FDA Approval Looks Imminent
The company agreed to the FDA's post-marketing requirements for a depression drug. 
Via Investor's Business Daily
Avicanna's Cannabinoid Drugs To Reach Brazil Via Its First 'Big Pharma' Deal
Via Benzinga
Syros' CDK12 Inhibitor Shows Anti Tumor Activity In Preclinical Studies
Syros Pharmaceuticals Inc (NASDAQ: SYRS)  
Via Benzinga
Expert Ratings For Jazz Pharmaceuticals
Over the past 3 months, 4 analysts have published their opinion on Jazz Pharmaceuticals (NASDAQ:JAZZ) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Raymond James reduced the price target on Intercontinental Exchange, Inc. (NYSE: ICE) from $161 to $157. Intercontinental Exchange shares rose 0.2% to $130.79 in pre-market trading. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
Upgrades 
Via Benzinga
Why Axsome Therapeutics Stock Is Trading Higher
Axsome Therapeutics Inc (NASDAQ: AXSM) is trading higher Monday morning after the company announced it will acquire Sunosi from Jazz Therapeutics PLC (NASDAQ: JAZZ). 
Via Benzinga
Axsome Acquires Sleep Disorder Drug From Jazz Pharma, Expanding Its Neuroscience Portfolio
Axsome Therapeutics Inc (NASDAQ: AXSM) has  
Via Benzinga
The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Jazz Pharmaceuticals's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q4, Jazz Pharmaceuticals's (NASDAQ:JAZZ) reported sales totaled $896.73 million. Despite a 33.09% increase in earnings, the company... 
Via Benzinga
Court Dismisses Canopy's Cannabis Patent Infringement Lawsuit Against Jazz's GW Pharma
The U.S. District Court for the Western District of Texas dismissed a lawsuit filed by Canadian cannabis giant C... 
Via Benzinga
Expert Ratings For Jazz Pharmaceuticals
Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total... 
Via Benzinga
Jazz Pharmaceuticals Announces Full Year And 4Q 2021 Financial Results
Jazz Pharmaceuticals plc (NASDAQ:JAZZ), a global biopharma... 
Via Benzinga
Jazz Pharmaceuticals: Q4 Earnings Insights
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine... 
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
This Company's 18-Month CBD Stability Achievement Could Hint Towards Expansion Goals As It Plans To Release First Commercial UST System In 2022
Photo by Kindel Media from Pexels This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Does This Company's Recent CBD Breakthrough Earn It A Spot In The Guinness World Records?
Photo by CBD Infos on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
New Psychedelics ETF Launches On NYSE Arca
Elemental Advisors Inc. has launched its first ETF, composed of companies involved in research, development, production or use of psychedelics to address medical conditions. The PSYK ETF (NYSE: PSYK)... 
Via Benzinga
The "Cannabis 50" List For 2021 Is Out, Is Your Favorite Company On It?
MGO (Macias Gini and O’Connell LLP), a leader in accounting, tax, audit and advisory solutions for the cannabis and hemp industries has released its 3rd annual “Cannabis 50” list. 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.